NCT05472948View on ClinicalTrials.gov

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2025

Conditions
Adenocarcinoma of Small IntestineAppendix CarcinomaMetastatic
Interventions
DRUG

Surufatinib

Surufatinib will be given 200/250 mg po. qd.

DRUG

Sintilimab

Sintilimab administered IV at a dose of 200mg every 3 weeks.

DRUG

Capecitabine

Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)

Trial Locations (1)

510655

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER